The study of efficacy, tolerability and safety of theophylline given along with formoterol plus budesonide in COPD

Journal of Clinical and Diagnostic Research

Volumn 9, Issue 2, 2015, Pages OC10-OC13

  Subramanian, S ^a   Ragulan, ^a   Jindal, Apar ^a   Vis Wambhar, V ^a   Arun Babu, V ^a  

^a CHETTINAD HOSPITAL AND RESEARCH INSTITUTE   (India)

Author keywords

COPD; CRP; Histone deacetylase; Theophylline

Indexed keywords

BRONCHODILATING AGENT; BUDESONIDE; C REACTIVE PROTEIN; FORMOTEROL; HEMOGLOBIN; HISTONE DEACETYLASE 2; PLACEBO; THEOPHYLLINE;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EXERCISE; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEADACHE; HEART PALPITATION; HUMAN; INSOMNIA; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFLAMMATION; SCORING SYSTEM; SINGLE BLIND PROCEDURE; SIX MINUTE WALK TEST; SPIROMETRY; TERTIARY CARE CENTER; THORAX PAIN;

EID: 84922263884     PISSN: 2249782X     EISSN: 0973709X     Source Type: Journal    
DOI: 10.7860/JCDR/2015/10803.5527     Document Type: Article

References (28)

1. G. Boyd, A. H. Morice, J. C. Pounsford, M. Siebert, N. Peslis, and C. Crawford, "An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD)," Eur. Respir. J. 1997;10(4):815-21.
2. T. A. Seemungal, G. C. Donaldson, E. A. Paul, J. C. Bestall, D. J. Jeffries, and J. A. Wedzicha, "Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.," Am. J. Respir. Crit. Care Med. 1998;157(5): 1418-22.
3. R. Casaburi, D. A. Mahler, P. W. Jones, A. Wanner, P. G. San, R. L. ZuWallack, S. S. Menjoge, C. W. Serby, and T. Witek, "A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease.," Eur. Respir. J. 2002;19(2):217-24.
4. M. R. Alexander, W. L. Dull, and J. E. Kasik. Treatment of chronic obstructive pulmonary disease with orally administered theophylline. A double-blind, controlled study. JAMA. 1980;244(20):2286-90.
5. M. L. Eaton, B. A. Green, T. R. Church, T. McGowan, and D. E. Niewoehner, "Efficacy of theophylline in 'irreversible' airflow obstruction.," Ann. Intern. Med. 1980;92(6):758-61.
6. D. Murciano, M. H. Auclair, R. Pariente, and M. Aubier, "A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease.," N. Engl. J. Med. 1989;320(23):1521-25.
7. G. Strategy, F. O. R. The, P. Of, C. Obstructive, and P. Disease, "Global Initiative for Chronic Obstructive Lung Disease," 2014.
8. B. G. Cosio, L. Tsaprouni, K. Ito, E. Jazrawi, I. M. Adcock, and P. J. Barnes. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J. Exp. Med. 2004;200(5):689-95.
9. P. J. Barnes. Theophylline for COPD. Thorax. 2006;61(9):742-44.
10. K. Ito, S. Lim, G. Caramori, B. Cosio, K. F. Chung, I. M. Adcock, et al. "A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression.," Proc. Natl. Acad. Sci. U. S. A. 2002;99(13):8921-26.
11. S. Yende, G. W. Waterer, E. A. Tolley, A. B. Newman, D. C. Bauer, D. R. Taaffe, et al. Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects., Thorax. 2006;61(1):10-16.
12. V. M. Pinto-Plata, H. Müllerova, J. F. Toso, M. Feudjo-Tepie, J. B. Soriano, R. S. Vessey, et al. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax. 2006;61(1):23-28.
13. K. L. Hattotuwa, M. J. Gizycki, T. W. Ansari, P. K. Jeffery, and N. C. Barnes. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am. J. Respir. Crit. Care Med. 2002;165(12):1592-96.
14. D. D. Sin, P. Lacy, E. York, and S. F. P. Man. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2004;170(7):760-65.
15. P. Calverley, R. Pauwels, J. Vestbo, P. Jones, N. Pride, A. Gulsvik, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003;361(9356)449-56.
16. D. M. Mannino, E. S. Ford, and S. C. Redd. Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. Am. J. Med. 2003;114(9):758-62.
17. M. Wadbo, C. G. Löfdahl, K. Larsson, B. E. Skoogh, G. Tornling, E. Arweström, et al. Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study. Eur. Respir. J. 2002;20(5):1138-46.
18. M. A. Dentener, E. C. Creutzberg, A. M. Schols, A. Mantovani, C. van't Veer, W. A. Buurman, et al., Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations. Thorax. 2001; 56(9):721-26.
19. M. A. Mendall, D. P. Strachan, B. K. Butland, L. Ballam, J. Morris, P. M. Sweetnam, et al. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur. Heart J. 2000;21(19):1584-90.
20. R. Broekhuizen, E. F. M. Wouters, E. C. Creutzberg, and A. M. W. J. Schols, Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax. 2006;61(1):17-22.
21. J. P. de Torres, E. Cordoba-Lanus, C. López-Aguilar, M. Muros de Fuentes, A. Montejo de Garcini, A. Aguirre-Jaime, et al. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur. Respir. J. 2006;27(5):902-07.
22. P. Weiner, R. Magadle, N. Berar-Yanay, A. Davidovich, and M. Weiner. The cumulative effect of long-acting bronchodilators, exercise, and inspiratory muscle training on the perception of dyspnea in patients with advanced COPD. Chest. 2000;118(3):672-78.
23. J. J. W. Liesker, P. J. Wijkstra, N. H. T. Ten Hacken, G. H. Koëter, D. S. Postma, and H. A. M. Kerstjens. A systematic review of the effects of bronchodilators on exercise capacity in patients with COPD. Chest. 2002;121(2):9608-597.
24. M. Cazzola, G. Di Lorenzo, F. Di Perna, F. Calderaro, R. Testi, and S. Centanni. Additive effects of salmeterol and fluticasone or theophylline in COPD. Chest. 2000;118(6):1576-81.
25. R. L. ZuWallack, D. A. Mahler, D. Reilly, N. Church, A. Emmett, K. Rickard, et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest. 2001;119(6):1661-70.
26. S. C. Eliane Cristina Zacarias, Aldemar Araujo Castro. Effect of theophylline associated with short-acting or long acting inhaled Beta 2 agonists in patients with stable chronic obstructive pulmonary disease: a systematic review. J Bras Pneumol. 2007; 33(2): 152 - 60.
27. A. Rossi, P. Kristufek, B. E. Levine, M. H. Thomson, D. Till, J. Kottakis, et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest. 2002;121(4):1058-69.
28. P. Thomas, J. A. Pugsley, and J. H. Stewart. Theophylline and salbutamol improve pulmonary function in patients with irreversible chronic obstructive pulmonary disease. Chest. 1992;101(1):160-65.